SYDNEY, July 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited ( ), (the ), the Company developing a new class of synthetic anti-infectives, is pleased to report promising results from its latest study on the efficacy of RECCE 327 (R327) against multidrug- resistant (MDR) World Health Organization (WHO) priority pathogen ( ). The study was conducted at Recce’s Anti-Infective Research (AIR) unit within Murdoch Children’s Research Institute. “These outstanding results highlight the potent efficacy of R327 in combating MDR bacteria, a significant global health challenge,” commented James Graham, CEO of Recce Pharmaceuticals.
“The ability of R327 to achieve such substantial reductions in bacterial load and maintain its effectiveness over 24 hours is a testament to its potential as a leading anti-infective treatment. We are excited about these findings and their implications for the future of infection management.” Dr.
Sohinee Sarkar, a leading researcher at Murdoch Children’s Research Institute, added, “The significant bactericidal activity observed with R327, particularly its ability to reduce bacterial presence to below the limit of detection, marks a major advancement in our fight against resistant pathogens. The sustained efficacy of R327 compared to ciprofloxacin underscores its potential as a superior treatment option. These results are promising and pave the way for further development and application of R327 in clinical settings.
” The study demo.
